Publicaciones en colaboración con investigadores/as de KU Leuven (20)

2024

  1. Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study

    The Lancet Rheumatology, Vol. 6, Núm. 6, pp. e374-e383

2023

  1. High-content multimodal analysis supports the IL-7/IL-7 receptor axis as a relevant therapeutic target in primary Sjögren's syndrome

    Journal of Autoimmunity

  2. Management of Psoriatic Arthritis in Patients With Comorbidities: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations

    The Journal of rheumatology, Vol. 50, Núm. 3, pp. 426-432

2022

  1. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

  2. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration

    Annals of the Rheumatic Diseases, Vol. 81, Núm. 10, pp. 1358-1366

  3. Implementation of recommendations in rheumatic and musculoskeletal diseases: considerations for development and uptake

    Annals of the Rheumatic Diseases, Vol. 81, Núm. 10, pp. 1344-1347

2021

  1. Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases

    Arthritis and Rheumatology, Vol. 73, Núm. 6, pp. 1073-1085

2020

  1. EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries

    Annals of the Rheumatic Diseases, Vol. 79, Núm. 11, pp. 1423-1431

2017

  1. A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis

    American Journal of Human Genetics, Vol. 100, Núm. 1, pp. 64-74

  2. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 6, pp. 960-977

  3. EULAR/PReS standards and recommendations for the transitional care of young people with juvenile-onset rheumatic diseases

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 4, pp. 639-646

2016

  1. Translation of clinical problems in osteoarthritis into pathophysiological research goals

    RMD Open, Vol. 2, Núm. 1

2015

  1. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: New analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE)

    Arthritis Research and Therapy, Vol. 17, Núm. 1

  2. Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology

    Annals of the Rheumatic Diseases, Vol. 74, Núm. 6, pp. 963-969

  3. Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis

    Annals of the Rheumatic Diseases, Vol. 74, Núm. 3, pp. 564-568

2012

  1. Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: A randomised, placebo controlled, proof-of-concept study

    Annals of the Rheumatic Diseases, Vol. 71, Núm. 2, pp. 180-185

2011

  1. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-Year outcomes

    Annals of the Rheumatic Diseases, Vol. 70, Núm. 11, pp. 1949-1956

2010

  1. CCR5 blockade in rheumatoid arthritis: A randomised, double-blind, placebo-controlled clinical trial

    Annals of the Rheumatic Diseases, Vol. 69, Núm. 11, pp. 2013-2016

2009

  1. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors

    Annals of the Rheumatic Diseases, Vol. 68, Núm. 12, pp. 1870-1877

  2. Large-scale analysis of association between GDF5 and FRZB variants and osteoarthritis of the hip, knee, and hand

    Arthritis and Rheumatism, Vol. 60, Núm. 6, pp. 1710-1721